Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP, 43607-43611 [2018-18519]
Download as PDF
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Proposed Rules
information about the proposed
significant new use rules, please see the
information provided in the direct final
action, with the same title, that is
located in the ‘‘Rules and Regulations’’
section of this issue of the Federal
Register.
List of Subjects in 40 CFR Part 721
Environmental protection, Chemicals,
Hazardous substances, Reporting and
recordkeeping requirements.
Dated: August 20, 2018.
Jeffery T. Morris,
Director, Office of Pollution Prevention and
Toxics.
[FR Doc. 2018–18528 Filed 8–24–18; 8:45 am]
BILLING CODE 6560–50–P
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 721
[EPA–HQ–OPPT–2017–0464; FRL–9982–25]
RIN 2070–AB27
Significant New Use Rules on Certain
Chemical Substances
Environmental Protection
Agency (EPA).
ACTION: Proposed rule.
amozie on DSK3GDR082PROD with PROPOSALS1
AGENCY:
SUMMARY: EPA is proposing significant
new use rules (SNURs) under the Toxic
Substances Control Act (TSCA) for 19
chemical substances which were the
subject of premanufacture notices
(PMNs). The chemical substances are
subject to Orders issued by EPA
pursuant to section 5(e) of TSCA. This
action would require persons who
intend to manufacture (defined by
statute to include import) or process any
of these 19 chemical substances for an
activity that is designated as a
significant new use by these rules to
notify EPA at least 90 days before
commencing that activity. The required
notification initiates EPA’s evaluation of
the intended use within the applicable
review period. Persons may not
commence manufacture or processing
for the significant new use until EPA
has conducted a review of the notice,
made an appropriate determination on
the notice, and has taken such actions
as are required with that determination.
In addition to this Notice of Proposed
Rulemaking, EPA is issuing the action
as a direct final rule elsewhere in this
issue of the Federal Register.
DATES: Comments must be received on
or before September 26, 2018.
ADDRESSES: Submit your comments,
identified by docket identification (ID)
VerDate Sep<11>2014
17:27 Aug 24, 2018
Jkt 244001
number EPA–HQ–OPPT–2017–0464, by
one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the online
instructions for submitting comments.
Do not submit electronically any
information you consider to be
Confidential Business Information (CBI)
or other information whose disclosure is
restricted by statute.
• Mail: Document Control Office
(7407M), Office of Pollution Prevention
and Toxics (OPPT), Environmental
Protection Agency, 1200 Pennsylvania
Ave. NW, Washington, DC 20460–0001.
• Hand Delivery: To make special
arrangements for hand delivery or
delivery of boxed information, please
follow the instructions at https://
www.epa.gov/dockets/contacts.html.
Additional instructions on commenting
or visiting the docket, along with more
information about dockets generally, is
available at https://www.epa.gov/
dockets.
For
technical information contact: Kenneth
Moss, Chemical Control Division
(7405M), Office of Pollution Prevention
and Toxics, Environmental Protection
Agency, 1200 Pennsylvania Ave. NW,
Washington, DC 20460–0001; telephone
number: (202) 564–9232; email address:
moss.kenneth@epa.gov.
For general information contact: The
TSCA-Hotline, ABVI-Goodwill, 422
South Clinton Ave., Rochester, NY
14620; telephone number: (202) 554–
1404; email address: TSCA-Hotline@
epa.gov.
FOR FURTHER INFORMATION CONTACT:
In
addition to this Notice of Proposed
Rulemaking, EPA is issuing the action
as a direct final rule elsewhere in this
issue of the Federal Register. For further
information about the proposed
significant new use rules, please see the
information provided in the direct final
action, with the same title, that is
located in the ‘‘Rules and Regulations’’
section of this issue of the Federal
Register.
SUPPLEMENTARY INFORMATION:
List of Subjects in 40 CFR Part 721
Environmental protection, Chemicals,
Hazardous substances, Reporting and
recordkeeping requirements.
Dated: August 17, 2018.
Jeffery T. Morris,
Director, Office of Pollution Prevention and
Toxics.
[FR Doc. 2018–18606 Filed 8–24–18; 8:45 am]
BILLING CODE 6560–50–P
PO 00000
Frm 00049
Fmt 4702
Sfmt 4702
43607
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
42 CFR Parts 1001 and 1003
RIN 0936–AA10
Medicare and State Health Care
Programs: Fraud and Abuse; Request
for Information Regarding the AntiKickback Statute and Beneficiary
Inducements CMP
Office of Inspector General
(OIG), HHS.
ACTION: Request for information.
AGENCY:
SUMMARY: This request for information
seeks input from the public on how to
address any regulatory provisions that
may act as barriers to coordinated care
or value-based care.
DATES: Comment Date: To ensure
consideration, comments must be
received at one of the addresses
provided below, no later than 5 p.m. on
October 26, 2018.
ADDRESSES: In commenting, refer to file
code OIG–0803–N. Because of staff and
resource limitations, we cannot accept
comments by facsimile (fax)
transmission. However, you may submit
comments in one of three ways (no
duplicates, please):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular, express, or overnight
mail. You may send written comments
to the following address: Susan
Edwards, Office of Inspector General,
Department of Health and Human
Services, Attention: OIG–0803–N, Room
5513, Cohen Building, 330
Independence Avenue SW, Washington,
DC 20201.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By hand or courier. If you prefer,
you may deliver your written comments
by hand or courier before the close of
the comment period to: Susan Edwards,
Office of Inspector General, Department
of Health and Human Services,
Attention: OIG–0803–N, Room 5513,
Cohen Building, 330 Independence
Avenue SW, Washington, DC 20201.
Because access to the interior of the
Cohen Building is not readily available
to persons without Federal Government
identification, commenters are
encouraged to schedule their delivery
with one of our staff members at (202)
619–0335.
E:\FR\FM\27AUP1.SGM
27AUP1
43608
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Proposed Rules
For information on viewing public
comments, please see the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Susan Edwards, (202) 708–9845.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments. Comments received
in a timely manner will also be available
for public inspection as they are
received at the Office of Inspector
General, Department of Health and
Human Services, Cohen Building, 330
Independence Avenue SW, Washington,
DC 20201, Monday through Friday, from
10 a.m. to 5 p.m. To schedule an
appointment to view public comments,
phone (202) 619–0335.
amozie on DSK3GDR082PROD with PROPOSALS1
I. Introduction
The Department of Health and Human
Services (HHS) is working to transform
the health care system into one that
better pays for value. Care coordination
is a key aspect of systems that deliver
value. Removing unnecessary
government obstacles to care
coordination is a key priority for HHS.
To help accelerate the transformation to
a value-based system that includes care
coordination, HHS has launched a
Regulatory Sprint to Coordinated Care,
led by the Deputy Secretary. This
‘‘Regulatory Sprint’’ is focused on
identifying regulatory provisions that
may act as barriers to coordinated care,
assessing whether those regulatory
provisions are unnecessary obstacles to
coordinated care, and issuing guidance
or revising regulations to address such
obstacles and, as appropriate, to
encourage and incentivize coordinated
care while protecting against harms
caused by fraud and abuse.
The Office of Inspector General (OIG)
seeks to identify ways in which it might
modify or add new safe harbors to the
anti-kickback statute and exceptions to
the beneficiary inducements civil
monetary penalty (CMP) definition of
‘‘remuneration’’ in order to foster
arrangements that would promote care
coordination and advance the delivery
of value-based care, while also
protecting against harms caused by
fraud and abuse. Through internal
VerDate Sep<11>2014
17:27 Aug 24, 2018
Jkt 244001
discussion and with the benefit of facts
and information received from external
stakeholders, OIG has identified the
broad reach of the anti-kickback statute
and beneficiary inducements CMP as a
potential impediment to beneficial
arrangements that would advance
coordinated care. To inform our efforts,
we welcome public comment on the
safe harbors to the anti-kickback statute
and the exceptions to the beneficiary
inducements CMP definition of
‘‘remuneration’’ as they relate to the
goals of the Regulatory Sprint outlined
above. In particular, we welcome
comments in response to the questions
presented in this Request for
Information (RFI).
II. Background
Section 1128B(b) of the Social
Security Act (the Act), the Federal antikickback statute, provides criminal
penalties for individuals or entities that
knowingly and willfully offer, pay,
solicit, or receive remuneration to
induce or reward the referral of business
reimbursable under Federal health care
programs, as defined in section 1128B(f)
of the Act. The law endeavors to protect
patients and the Federal health care
programs from fraud and abuse by
curtailing the corrupting influence of
remuneration on health care decisions;
however, because the statute is broadly
written, when it was enacted there was
concern that some relatively innocuous
and potentially beneficial arrangements
were technically covered by the statute
and therefore were subject to criminal
prosecution.
In response to this concern, Congress
passed section 14 of the Medicare and
Medicaid Patient and Program
Protection Act of 1987, which required
HHS to set forth ‘‘safe harbors’’ to the
anti-kickback statute. Specifically,
section 1128B(b)(3)(E) of the Act
protects from the anti-kickback statute
‘‘any payment practice specified by the
Secretary in regulations promulgated
pursuant to section 14(a) of the
Medicare and Medicaid Patient and
Program Protection Act of 1987.’’ In
giving HHS the authority to protect
certain arrangements and payment
practices under the anti-kickback
statute, Congress intended the safe
harbors to be evolving rules that would
be updated periodically to reflect
changing business practices and
technologies in the health care
industry.1
Health care providers and others may
voluntarily comply with safe harbors in
an effort to ensure that their business
practices will not be subject to criminal
1 H.R.
PO 00000
Rep. No. 100–85, Pt. 2, at 27 (1987).
Frm 00050
Fmt 4702
Sfmt 4702
prosecution under the anti-kickback
statute, the imposition of civil monetary
penalties (CMPs) under section
1128A(a)(7) of the Act, program
exclusion under section 1128(b)(7) of
the Act, and liability under the False
Claims Act (31 U.S.C. 3729–33). Since
finalizing the first safe harbors in 1991,
OIG has continued to engage the
industry on the application of the
Federal anti-kickback statute and
development of safe harbors.
Section 1128A(a)(5) of the Act, the
beneficiary inducements CMP, provides
for the imposition of CMPs against any
person who offers or transfers
remuneration to a Medicare or State
health care program beneficiary that the
benefactor knows or should know is
likely to influence the beneficiary’s
selection of a particular provider,
practitioner, or supplier of any item or
service for which payment may be
made, in whole or in part, by Medicare
or a State health care program. In the
same administrative proceedings in
which it may seek to impose CMPs
against a person, OIG may seek to
exclude such person from the Federal
health care programs. For purposes of
section 1128A(a)(5) of the Act, the
statute defines ‘‘remuneration’’ to
include, without limitation, waivers of
co-payments and deductible amounts
(or any part thereof) and transfers of
items or services for free or for other
than fair market value.2 The statute and
associated regulations contain a limited
number of exceptions.3
OIG is mindful of the impact of
delivery system and payment reform on
Federal health care programs and the
changing relationships between
providers, suppliers, and other entities
in delivering higher quality, better
coordinated care; enhancing value; and
improving the overall health of patients.
We have received several suggestions
for new safe harbors and proposed
modifications to existing safe harbors
that may promote care coordination and
reduce regulatory impediments to valuebased arrangements, including in
response to our annual ‘‘Solicitation of
New Safe Harbors and Special Fraud
Alerts.’’ 4
We continue to consider how to
balance additional flexibility for
industry stakeholders to provide
2 See
section 1128A(i)(6) of the Act.
id.; 42 CFR 1003.110.
4 See, e.g., Solicitation of New Safe Harbors and
Special Fraud Alerts, 82 FR 61,229 (Dec. 27, 2017),
available at https://www.gpo.gov/fdsys/pkg/FR2017-12-27/pdf/2017-27117.pdf; OIG, Semiannual
Report to Congress, April 1, 2017–September 30,
2017, available at https://oig.hhs.gov/reports-andpublications/archives/semiannual/2017/sar-fall2017.pdf.
3 See
E:\FR\FM\27AUP1.SGM
27AUP1
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Proposed Rules
efficient, well-coordinated, patientcentered care with protections against
the harms caused by fraud and abuse.
We are requesting additional
information in this RFI to help inform
our efforts. We are particularly
interested in thoughts on topics that
include, but are not limited to: (i) The
structure of arrangements between
parties that participate in alternative
payment models or other novel financial
arrangements designed to promote care
coordination and value; (ii) the need for
new or revised safe harbors and
exceptions to the definition of
‘‘remuneration’’ under the beneficiary
inducements CMP to promote beneficial
care coordination, patient engagement,
and value-based arrangements; and (iii)
terminology related to alternative
payment models, value-based
arrangements, and care coordination.
We are interested in any special
considerations for rural providers and
others serving underserved populations,
including American Indian and Alaska
Native communities.
Where relevant, we intend to review
comments submitted in response to the
Medicare Program; Request for
Information Regarding the Physician
Self-Referral Law, RIN 0938–AT64,
issued by the Centers for Medicare &
Medicaid Services (CMS).5 However,
given the volume of questions included
in that RFI and OIG’s separate, and
different, authorities, we urge
individuals and entities to resubmit any
relevant comments to this RFI to ensure
they are considered by OIG. We look
forward to receiving input in response
to this RFI.
amozie on DSK3GDR082PROD with PROPOSALS1
III. Request for Information
We welcome public input on any or
all of the topics identified below.
Respondents are not required to address
every issue or respond to every question
discussed in this RFI to have their
responses considered.
1. Promoting Care Coordination and
Value-Based Care
A. Please tell us about potential
arrangements that the industry is
interested in pursuing, such as care
coordination, value-based arrangements,
alternative payment models,
arrangements involving innovative
technology, and other novel financial
arrangements that may implicate the
anti-kickback statute or beneficiary
inducements CMP. For example, we are
interested in better understanding the
5 Medicare Program; Request for Information
Regarding the Physician Self-Referral Law, 83 FR
29,524 (June 25, 2018), available at https://
www.gpo.gov/fdsys/pkg/FR-2018-06-25/pdf/201813529.pdf.
VerDate Sep<11>2014
17:27 Aug 24, 2018
Jkt 244001
structure and terms of the arrangement
(e.g., categories/types of parties; how
risk is allocated among parties; financial
relationships involving potential referral
sources and seekers created by the
arrangement; and types of items and
services provided by the arrangement).
We are also interested in understanding
how the arrangement promotes care
coordination or value-based care and
how the arrangement prevents potential
harms, such as increased costs,
inappropriate utilization, poor quality of
care, and distorted decision making.
B. Please identify what, if any,
additional or modified safe harbors to
the anti-kickback statute or exceptions
to the definition of ‘‘remuneration’’
under the beneficiary inducements CMP
may be necessary to protect such
arrangements and any key provisions
that should be included in the
additional or modified safe harbor or
exception. Existing safe harbors and
exceptions of particular relevance to
coordinated care include, for example,
those related to personal services and
management contracts, electronic health
record arrangements, warranties,
transportation, and promoting access to
care. Suggested new safe harbors or
exceptions might address care
coordination services arrangements or
arrangements promoting the use of
innovative technology. In particular,
please describe what conditions would
be appropriate to include in a safe
harbor or exception to protect against
fraud and abuse in the context of such
arrangements, including what, if any,
disclosures should be required by such
safe harbors or exceptions.
C. Please explain how ‘‘value’’ could
be defined and used in a safe harbor or
exception such that OIG could evaluate
‘‘value’’ within an arrangement to
determine compliance with the safe
harbor or exception.
D. In the context of health care
delivery reform, payment reform, and
the anti-kickback statute, please share
thoughts on definitions for critical
terminology such as:
i. Alternative payment model
ii. Care coordination services
iii. Care coordinator
iv. Clinical integration
v. Coordinated care
vi. Financial integration
vii. Gainsharing
viii. Health system
ix. Integrated care model
x. Integrated delivery system
xi. Incentive payments
xii. Outcomes-based care
xiii. Risk
xiv. Risk-sharing
xv. Value-based care
PO 00000
Frm 00051
Fmt 4702
Sfmt 4702
43609
xvi. Value-based arrangement
E. Are there opportunities where OIG
could clarify its position through
guidance as opposed to regulation? For
example, would a law enforcement
policy statement offer sufficient
protection in some instances? If so,
please elaborate.
2. Beneficiary Engagement
A. Beneficiary Incentives
i. Please provide feedback regarding
the types of incentives providers,
suppliers, and others are interested in
providing to beneficiaries, how
providing such incentives would
contribute to or improve quality of care,
care coordination, and patient
engagement, including adherence to
care plans, and whether the types of
providers, suppliers, or other entities
that furnish the incentives matter from
an effectiveness and program integrity
perspective. Please be as specific as
possible. Additional areas of interest
include:
a. What, if any, restrictions should
OIG place on the sources, types, or
frequency of beneficiary incentives that
could be provided to reduce the risk of
fraud and abuse?
b. Examples of beneficiary incentive
arrangements that are appropriate and
effective.
c. Should beneficiary incentives
connected to medication adherence and
medication management be treated
differently than other types of
beneficiary incentives? If so, how and
why?
d. What, if any, disclosures should
OIG require the offeror to make to
beneficiaries regarding an incentive
(e.g., the source of the incentive)?
ii. Please identify (and provide
citations to) any recent studies assessing
the positive or negative effects of
beneficiary incentives on patient care or
patient engagement.
iii. In the context of beneficiary
incentives, please identify any risks or
benefits from the following types of
potential remuneration, as well as any
safeguards to mitigate risks, and
describe how these terms should be
defined for purposes of any rulemaking
related to coordinated care or valuebased arrangements:
a. Cash equivalent
b. Gift card
c. In-kind items and services
d. Nonmonetary remuneration
iv. To promote care coordination and
value-based care, should OIG amend its
‘‘Office of Inspector General Policy
Statement Regarding Gifts of Nominal
Value To Medicare and Medicaid
E:\FR\FM\27AUP1.SGM
27AUP1
43610
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Proposed Rules
Beneficiaries’’ 6 to increase ‘‘nominal
value’’ from no more than $15 per item
or $75 in the aggregate per patient on an
annual basis? If so, why? Please provide
data or other support for any suggested
changes in the dollar amounts. Also,
please provide input on whether OIG
should have a similar policy under the
anti-kickback statute and, if so, how
such policy would contribute to care
coordination or value-based care.
B. Cost-Sharing Obligations
i. We are interested in input about
how relieving or eliminating beneficiary
cost-sharing obligations might improve
care delivery, enhance value-based
arrangements, and promote quality of
care. Please describe any patient care
scenarios in which cost-sharing
obligations are particularly problematic.
ii. Please describe the financial
impact on providers, suppliers, and
other entities, as well as the fraud and
abuse risks, if cost-sharing amounts
could be waived (i.e., the amount owed
is not paid) by participants in a care
coordination or value-based
arrangement. What, if any, concerns
arise if cost-sharing obligations could be
subsidized by providers, suppliers, or
other entities in a care delivery
arrangement?
iii. Please describe any risks to
beneficiaries and Federal health care
programs from the reduction or
elimination of cost-sharing obligations.
iv. Please describe any suggested
protections or safeguards that OIG
should incorporate if we were to create
a safe harbor for certain beneficiary costsharing waiver or subsidy arrangements.
3. Other Related Topics of Interest
amozie on DSK3GDR082PROD with PROPOSALS1
A. Current Fraud and Abuse Waivers
i. Please provide feedback on the
current waivers developed for the
purposes of testing models by the Center
for Medicare and Medicaid Innovation
(Innovation Center) and carrying out the
Medicare Shared Savings Program
(MSSP).7 Feedback from parties who are
using or who are eligible to use those
waivers would be helpful as we
consider the issues raised in this RFI.
For example, we are interested in the
following:
a. How, if at all, have stakeholders
found compliance with the waiver
6 OIG, Office of Inspector General Policy
Statement Regarding Gifts of Nominal Value To
Medicare and Medicaid Beneficiaries (Dec. 7, 2016),
available at https://oig.hhs.gov/fraud/docs/
alertsandbulletins/OIG-Policy-Statement-Gifts-ofNominal-Value.pdf.
7 CMS, Fraud and Abuse Waivers for Select CMS
Models and Programs, available at https://
www.cms.gov/Medicare/Fraud-and-Abuse/Physicia
nSelfReferral/Fraud-and-Abuse-Waivers.html.
VerDate Sep<11>2014
17:27 Aug 24, 2018
Jkt 244001
conditions challenging? Please be as
specific as possible.
b. Are any waiver requirements
particularly burdensome, such that they
impede the goals of the models,
initiatives, or programs? If so, please
specify which waiver requirements and
why they impede the goals of the model,
initiative, or program.
c. What waiver structures or
conditions, if any, work well? Should
OIG consider any waiver structures or
conditions for any future safe harbors or
exceptions related to care coordination
and value-based care (including
beneficiary incentives to promote
patient engagement)? Please be as
specific as possible and provide reasons.
d. One of the key safeguards to
mitigate the risk of fraud or abuse from
arrangements protected by the preparticipation and participation waivers
developed pursuant to the MSSP, the
Next Generation ACO Model’s
participation waiver, and the Pioneer
ACO Model’s participation waiver 8 is
the involvement of the accountable care
organization’s (ACO’s) governing body
in the authorization of each
arrangement. We are interested in
feedback on how the ACO governing
body concept is working, and whether
and if so how, it could be applied to safe
harbors or exceptions for alternative
payment models and coordinated care
arrangements.
e. We invite specific feedback
regarding the pros and cons of fraud and
abuse protections (e.g., waivers or safe
harbors) that are uniform across
different types of CMS-sponsored
models, initiatives, and programs.
testing services, training services,
monitoring services, or repair or
maintenance services). Other areas of
interest include:
a. How might such items or services
reduce cybersecurity risks to the
following: The donor, the recipient,
patients, and other nonparties to the
arrangement?
b. Are there technical or legal barriers
(besides the physician self-referral law
and the anti-kickback statute) that could
prevent or limit the arrangements?
c. Are there any potential risks or
unintended consequences to such
arrangements (e.g., potential for fraud or
abuse, information blocking, or anticompetitive practices) and, if so, how
might these risks be mitigated?
d. Are there any particular risks if
HHS takes no action?
C. ACO Beneficiary Incentive Program
(Section 50341(b) of the Bipartisan
Budget Act of 2018) 9
Section 50341(b) of the Bipartisan
Budget Act of 2018, which added
section 1128B(b)(3)(K) of the Act, states
that ‘‘illegal remuneration’’ under the
anti-kickback statute does not include
‘‘. . . an incentive payment made to a
Medicare fee-for-service beneficiary by
an ACO under an ACO Beneficiary
Incentive Program established under
subsection (m) of section 1899, if the
payment is made in accordance with the
requirements of such subsection and
meets such other conditions as the
Secretary may establish.’’
i. For the purposes of implementing
this new statutory exception through a
safe harbor, what, if any, ‘‘other
conditions’’ should this safe harbor
include as protections or safeguards?
Please provide supporting reasons.
B. Cybersecurity-Related Items and
Services
i. We are aware of interest in donating
or subsidizing cybersecurity-related
items and services to providers and
others with whom they share
information. We are interested in
information about the types of
cybersecurity-related items or services
that entities wish to donate or subsidize,
and how existing fraud and abuse laws
may pose barriers to such arrangements.
For example, we are interested in (i) the
types of persons that would be parties
to, or benefit from, such arrangements;
(ii) whether any persons should be
excluded from such arrangements; (iii)
the particular types of items that would
be involved in such arrangements (e.g.,
hardware, software, and other items);
and (iv) the types of services that would
be involved in such arrangements (e.g.,
Section 50302(c) of the Bipartisan
Budget Act of 2018 creates a new
exception to the definition of
‘‘remuneration’’ in the beneficiary
inducements CMP. This exception
applies to ‘‘telehealth technologies’’
provided on or after January 1, 2019, by
a provider of services or a renal dialysis
facility to an individual with end-stage
renal disease (ESRD) who is receiving
home dialysis for which payment is
being made under Medicare Part B.
Under the statute, ‘‘telehealth
technologies’’ is a term to be defined by
the Secretary. The exception requires
that (i) the telehealth technologies not
be offered as part of any advertisement
8 The Pioneer ACO model began in 2012, and the
final performance year concluded on December 31,
2016.
9 Bipartisan Budget Act of 2018, Public Law 115–
123, 115th Cong. (2018) (enacted).
10 Id.
PO 00000
Frm 00052
Fmt 4702
Sfmt 4702
D. Telehealth (Section 50302(c) of the
Bipartisan Budget Act of 2018) 10
E:\FR\FM\27AUP1.SGM
27AUP1
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Proposed Rules
amozie on DSK3GDR082PROD with PROPOSALS1
or solicitation; (ii) the telehealth
technologies must be provided for the
purpose of furnishing telehealth
services related to the patient’s ESRD;
and (iii) the provision of the telehealth
technologies must ‘‘meet[] any other
requirements set forth in regulations
promulgated by the Secretary.’’
i. For the purposes of this exception,
please provide input on how ‘‘telehealth
technologies’’ should be defined. Please
provide examples of telehealth
technologies that may be used to furnish
telehealth services related to a
beneficiary’s ESRD (e.g., technologies
that address services on the Medicare
telehealth list). Also, please indicate
whether telehealth technologies should
include services. If so, please explain, in
detail, what services should be
considered ‘‘telehealth technologies.’’
ii. For the purposes of this exception,
should OIG include protections or
safeguards as ‘‘any other requirements
set forth in regulations promulgated by
the Secretary?’’ If so, please explain
what protections or safeguards and why.
4. Intersection of Physician Self-Referral
Law and Anti-Kickback Statute
Please share any feedback regarding
specific circumstances in which (i)
exceptions to the physician self-referral
law and safe harbors to the antikickback statute should align for
purposes of the goals of this RFI; and (ii)
exceptions to the physician self-referral
law in furtherance of care coordination
or value-based care should not have a
corresponding safe harbor to the antikickback statute.
Respondents are encouraged to
provide complete but concise and
organized responses, including any
relevant data and specific examples.
Respondents are not required to address
every issue or respond to every question
discussed in this RFI to have their
responses considered. All responses
will be considered, provided they
contain information OIG can use to
identify the commenter.
Please note: This is a request for
information only. This RFI is issued
solely for information and planning
purposes; it does not constitute a
Request for Proposal (RFP), application,
proposal abstract, or quotation. This RFI
does not commit the U.S. Government
to contract for any supplies or services
or make a grant award. Further, OIG is
not seeking proposals through this RFI
and will not accept unsolicited
proposals. Respondents are advised that
the U.S. Government will not pay for
any information or administrative costs
incurred in response to this RFI; all
costs associated with responding to this
RFI will be solely at the interested
VerDate Sep<11>2014
17:27 Aug 24, 2018
Jkt 244001
party’s expense. Not responding to this
RFI does not preclude participation in
any future procurement, if conducted. It
is the responsibility of the potential
responders to monitor this RFI
announcement for additional
information pertaining to this request.
Please note that OIG will not respond to
questions about the policy issues raised
in this RFI. Contractor support
personnel may be used to review RFI
responses.
Responses to this RFI are not offers
and cannot be accepted by the U.S.
Government to form a binding contract
or issue a grant. Information obtained as
a result of this RFI may be used by the
U.S. Government for program planning
on a nonattribution basis. Respondents
should not include any information that
might be considered proprietary or
confidential. This RFI should not be
construed as a commitment or
authorization to incur costs for which
reimbursement would be required or
sought. All submissions become U.S.
Government property and will not be
returned. OIG may publicly post the
comments received or a summary
thereof.
IV. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
However, section III of this document
does contain a general solicitation of
comments in the form of a request for
information. In accordance with the
implementing regulations of the
Paperwork Reduction Act (PRA),
specifically 5 CFR 1320.3(h)(4), this
general solicitation is exempt from the
PRA. Facts or opinions submitted in
response to general solicitations of
comments from the public, published in
the Federal Register or other
publications, regardless of the form or
format thereof, provided that no person
is required to supply specific
information pertaining to the
commenter, other than that necessary
for self-identification, as a condition of
the agency’s full consideration, are not
generally considered information
subject to the PRA. Consequently, there
is no need for review by the Office of
Management and Budget under the
authority of the PRA (44 U.S.C. 3501 et
seq.).
V. Response to Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
PO 00000
Frm 00053
Fmt 4702
Sfmt 4702
43611
comments we receive by the date and
time specified in the DATES section of
this preamble, and, if we proceed with
a subsequent document, we may
respond to the comments in the
preamble to that document.
Dated: August 20, 2018.
Daniel R. Levinson,
Inspector General.
[FR Doc. 2018–18519 Filed 8–24–18; 8:45 am]
BILLING CODE 4152–01–P
DEPARTMENT OF THE INTERIOR
Office of the Secretary
43 CFR Part 11
[Docket No. DOI–2018–0006; XXXD5198NI.
DS61600000.DNINR0000.000000.DX61604]
RIN 1090–AB17
Natural Resource Damages for
Hazardous Substances
Office of Restoration and
Damage Assessment, Interior.
ACTION: Advance notice of proposed
rulemaking; request for public
comment.
AGENCY:
SUMMARY: The Office of Restoration and
Damage Assessment (ORDA) is seeking
comments and suggestions from State,
Tribal, and Federal natural resource cotrustees, other affected parties, and the
interested public on whether revisions
to the regulations for conducting natural
resource damage assessments and
restoration (NRDAR) for hazardous
substance releases are needed, and if so,
what specific revisions should be
considered.
We will accept comments
through October 26, 2018.
ADDRESSES: You may submit comments
to ORDA on this ANPRM by any of the
following methods. Please reference the
Regulation Identifier Number (RIN)
DOI–2018–0006 in your comments.
• Electronically: Go to https://
www.regulations.gov. In the ‘‘Search’’
box enter ‘‘DOI–2018–0006.’’ Follow the
instructions to submit public comments.
We will post all comments.
• Hand deliver or mail comments to
the Office of Restoration and Damage
Assessment, U.S. Department of the
Interior, 1849 C Street Northwest, Mail
Stop/Room 5538, Washington, DC
20240.
DATES:
FOR FURTHER INFORMATION CONTACT:
Steve Glomb, Director, Office of
Restoration and Damage Assessment at
(202) 208–4863 or email to steve_
glomb@ios.doi.gov.
E:\FR\FM\27AUP1.SGM
27AUP1
Agencies
[Federal Register Volume 83, Number 166 (Monday, August 27, 2018)]
[Proposed Rules]
[Pages 43607-43611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-18519]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of Inspector General
42 CFR Parts 1001 and 1003
RIN 0936-AA10
Medicare and State Health Care Programs: Fraud and Abuse; Request
for Information Regarding the Anti-Kickback Statute and Beneficiary
Inducements CMP
AGENCY: Office of Inspector General (OIG), HHS.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: This request for information seeks input from the public on
how to address any regulatory provisions that may act as barriers to
coordinated care or value-based care.
DATES: Comment Date: To ensure consideration, comments must be received
at one of the addresses provided below, no later than 5 p.m. on October
26, 2018.
ADDRESSES: In commenting, refer to file code OIG-0803-N. Because of
staff and resource limitations, we cannot accept comments by facsimile
(fax) transmission. However, you may submit comments in one of three
ways (no duplicates, please):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular, express, or overnight mail. You may send written
comments to the following address: Susan Edwards, Office of Inspector
General, Department of Health and Human Services, Attention: OIG-0803-
N, Room 5513, Cohen Building, 330 Independence Avenue SW, Washington,
DC 20201.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By hand or courier. If you prefer, you may deliver your written
comments by hand or courier before the close of the comment period to:
Susan Edwards, Office of Inspector General, Department of Health and
Human Services, Attention: OIG-0803-N, Room 5513, Cohen Building, 330
Independence Avenue SW, Washington, DC 20201.
Because access to the interior of the Cohen Building is not readily
available to persons without Federal Government identification,
commenters are encouraged to schedule their delivery with one of our
staff members at (202) 619-0335.
[[Page 43608]]
For information on viewing public comments, please see the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Susan Edwards, (202) 708-9845.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following
website as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that website to
view public comments. Comments received in a timely manner will also be
available for public inspection as they are received at the Office of
Inspector General, Department of Health and Human Services, Cohen
Building, 330 Independence Avenue SW, Washington, DC 20201, Monday
through Friday, from 10 a.m. to 5 p.m. To schedule an appointment to
view public comments, phone (202) 619-0335.
I. Introduction
The Department of Health and Human Services (HHS) is working to
transform the health care system into one that better pays for value.
Care coordination is a key aspect of systems that deliver value.
Removing unnecessary government obstacles to care coordination is a key
priority for HHS. To help accelerate the transformation to a value-
based system that includes care coordination, HHS has launched a
Regulatory Sprint to Coordinated Care, led by the Deputy Secretary.
This ``Regulatory Sprint'' is focused on identifying regulatory
provisions that may act as barriers to coordinated care, assessing
whether those regulatory provisions are unnecessary obstacles to
coordinated care, and issuing guidance or revising regulations to
address such obstacles and, as appropriate, to encourage and
incentivize coordinated care while protecting against harms caused by
fraud and abuse.
The Office of Inspector General (OIG) seeks to identify ways in
which it might modify or add new safe harbors to the anti-kickback
statute and exceptions to the beneficiary inducements civil monetary
penalty (CMP) definition of ``remuneration'' in order to foster
arrangements that would promote care coordination and advance the
delivery of value-based care, while also protecting against harms
caused by fraud and abuse. Through internal discussion and with the
benefit of facts and information received from external stakeholders,
OIG has identified the broad reach of the anti-kickback statute and
beneficiary inducements CMP as a potential impediment to beneficial
arrangements that would advance coordinated care. To inform our
efforts, we welcome public comment on the safe harbors to the anti-
kickback statute and the exceptions to the beneficiary inducements CMP
definition of ``remuneration'' as they relate to the goals of the
Regulatory Sprint outlined above. In particular, we welcome comments in
response to the questions presented in this Request for Information
(RFI).
II. Background
Section 1128B(b) of the Social Security Act (the Act), the Federal
anti-kickback statute, provides criminal penalties for individuals or
entities that knowingly and willfully offer, pay, solicit, or receive
remuneration to induce or reward the referral of business reimbursable
under Federal health care programs, as defined in section 1128B(f) of
the Act. The law endeavors to protect patients and the Federal health
care programs from fraud and abuse by curtailing the corrupting
influence of remuneration on health care decisions; however, because
the statute is broadly written, when it was enacted there was concern
that some relatively innocuous and potentially beneficial arrangements
were technically covered by the statute and therefore were subject to
criminal prosecution.
In response to this concern, Congress passed section 14 of the
Medicare and Medicaid Patient and Program Protection Act of 1987, which
required HHS to set forth ``safe harbors'' to the anti-kickback
statute. Specifically, section 1128B(b)(3)(E) of the Act protects from
the anti-kickback statute ``any payment practice specified by the
Secretary in regulations promulgated pursuant to section 14(a) of the
Medicare and Medicaid Patient and Program Protection Act of 1987.'' In
giving HHS the authority to protect certain arrangements and payment
practices under the anti-kickback statute, Congress intended the safe
harbors to be evolving rules that would be updated periodically to
reflect changing business practices and technologies in the health care
industry.\1\
---------------------------------------------------------------------------
\1\ H.R. Rep. No. 100-85, Pt. 2, at 27 (1987).
---------------------------------------------------------------------------
Health care providers and others may voluntarily comply with safe
harbors in an effort to ensure that their business practices will not
be subject to criminal prosecution under the anti-kickback statute, the
imposition of civil monetary penalties (CMPs) under section 1128A(a)(7)
of the Act, program exclusion under section 1128(b)(7) of the Act, and
liability under the False Claims Act (31 U.S.C. 3729-33). Since
finalizing the first safe harbors in 1991, OIG has continued to engage
the industry on the application of the Federal anti-kickback statute
and development of safe harbors.
Section 1128A(a)(5) of the Act, the beneficiary inducements CMP,
provides for the imposition of CMPs against any person who offers or
transfers remuneration to a Medicare or State health care program
beneficiary that the benefactor knows or should know is likely to
influence the beneficiary's selection of a particular provider,
practitioner, or supplier of any item or service for which payment may
be made, in whole or in part, by Medicare or a State health care
program. In the same administrative proceedings in which it may seek to
impose CMPs against a person, OIG may seek to exclude such person from
the Federal health care programs. For purposes of section 1128A(a)(5)
of the Act, the statute defines ``remuneration'' to include, without
limitation, waivers of co-payments and deductible amounts (or any part
thereof) and transfers of items or services for free or for other than
fair market value.\2\ The statute and associated regulations contain a
limited number of exceptions.\3\
---------------------------------------------------------------------------
\2\ See section 1128A(i)(6) of the Act.
\3\ See id.; 42 CFR 1003.110.
---------------------------------------------------------------------------
OIG is mindful of the impact of delivery system and payment reform
on Federal health care programs and the changing relationships between
providers, suppliers, and other entities in delivering higher quality,
better coordinated care; enhancing value; and improving the overall
health of patients. We have received several suggestions for new safe
harbors and proposed modifications to existing safe harbors that may
promote care coordination and reduce regulatory impediments to value-
based arrangements, including in response to our annual ``Solicitation
of New Safe Harbors and Special Fraud Alerts.'' \4\
---------------------------------------------------------------------------
\4\ See, e.g., Solicitation of New Safe Harbors and Special
Fraud Alerts, 82 FR 61,229 (Dec. 27, 2017), available at https://www.gpo.gov/fdsys/pkg/FR-2017-12-27/pdf/2017-27117.pdf; OIG,
Semiannual Report to Congress, April 1, 2017-September 30, 2017,
available at https://oig.hhs.gov/reports-and-publications/archives/semiannual/2017/sar-fall-2017.pdf.
---------------------------------------------------------------------------
We continue to consider how to balance additional flexibility for
industry stakeholders to provide
[[Page 43609]]
efficient, well-coordinated, patient-centered care with protections
against the harms caused by fraud and abuse. We are requesting
additional information in this RFI to help inform our efforts. We are
particularly interested in thoughts on topics that include, but are not
limited to: (i) The structure of arrangements between parties that
participate in alternative payment models or other novel financial
arrangements designed to promote care coordination and value; (ii) the
need for new or revised safe harbors and exceptions to the definition
of ``remuneration'' under the beneficiary inducements CMP to promote
beneficial care coordination, patient engagement, and value-based
arrangements; and (iii) terminology related to alternative payment
models, value-based arrangements, and care coordination. We are
interested in any special considerations for rural providers and others
serving underserved populations, including American Indian and Alaska
Native communities.
Where relevant, we intend to review comments submitted in response
to the Medicare Program; Request for Information Regarding the
Physician Self-Referral Law, RIN 0938-AT64, issued by the Centers for
Medicare & Medicaid Services (CMS).\5\ However, given the volume of
questions included in that RFI and OIG's separate, and different,
authorities, we urge individuals and entities to resubmit any relevant
comments to this RFI to ensure they are considered by OIG. We look
forward to receiving input in response to this RFI.
---------------------------------------------------------------------------
\5\ Medicare Program; Request for Information Regarding the
Physician Self-Referral Law, 83 FR 29,524 (June 25, 2018), available
at https://www.gpo.gov/fdsys/pkg/FR-2018-06-25/pdf/2018-13529.pdf.
---------------------------------------------------------------------------
III. Request for Information
We welcome public input on any or all of the topics identified
below. Respondents are not required to address every issue or respond
to every question discussed in this RFI to have their responses
considered.
1. Promoting Care Coordination and Value-Based Care
A. Please tell us about potential arrangements that the industry is
interested in pursuing, such as care coordination, value-based
arrangements, alternative payment models, arrangements involving
innovative technology, and other novel financial arrangements that may
implicate the anti-kickback statute or beneficiary inducements CMP. For
example, we are interested in better understanding the structure and
terms of the arrangement (e.g., categories/types of parties; how risk
is allocated among parties; financial relationships involving potential
referral sources and seekers created by the arrangement; and types of
items and services provided by the arrangement). We are also interested
in understanding how the arrangement promotes care coordination or
value-based care and how the arrangement prevents potential harms, such
as increased costs, inappropriate utilization, poor quality of care,
and distorted decision making.
B. Please identify what, if any, additional or modified safe
harbors to the anti-kickback statute or exceptions to the definition of
``remuneration'' under the beneficiary inducements CMP may be necessary
to protect such arrangements and any key provisions that should be
included in the additional or modified safe harbor or exception.
Existing safe harbors and exceptions of particular relevance to
coordinated care include, for example, those related to personal
services and management contracts, electronic health record
arrangements, warranties, transportation, and promoting access to care.
Suggested new safe harbors or exceptions might address care
coordination services arrangements or arrangements promoting the use of
innovative technology. In particular, please describe what conditions
would be appropriate to include in a safe harbor or exception to
protect against fraud and abuse in the context of such arrangements,
including what, if any, disclosures should be required by such safe
harbors or exceptions.
C. Please explain how ``value'' could be defined and used in a safe
harbor or exception such that OIG could evaluate ``value'' within an
arrangement to determine compliance with the safe harbor or exception.
D. In the context of health care delivery reform, payment reform,
and the anti-kickback statute, please share thoughts on definitions for
critical terminology such as:
i. Alternative payment model
ii. Care coordination services
iii. Care coordinator
iv. Clinical integration
v. Coordinated care
vi. Financial integration
vii. Gainsharing
viii. Health system
ix. Integrated care model
x. Integrated delivery system
xi. Incentive payments
xii. Outcomes-based care
xiii. Risk
xiv. Risk-sharing
xv. Value-based care
xvi. Value-based arrangement
E. Are there opportunities where OIG could clarify its position
through guidance as opposed to regulation? For example, would a law
enforcement policy statement offer sufficient protection in some
instances? If so, please elaborate.
2. Beneficiary Engagement
A. Beneficiary Incentives
i. Please provide feedback regarding the types of incentives
providers, suppliers, and others are interested in providing to
beneficiaries, how providing such incentives would contribute to or
improve quality of care, care coordination, and patient engagement,
including adherence to care plans, and whether the types of providers,
suppliers, or other entities that furnish the incentives matter from an
effectiveness and program integrity perspective. Please be as specific
as possible. Additional areas of interest include:
a. What, if any, restrictions should OIG place on the sources,
types, or frequency of beneficiary incentives that could be provided to
reduce the risk of fraud and abuse?
b. Examples of beneficiary incentive arrangements that are
appropriate and effective.
c. Should beneficiary incentives connected to medication adherence
and medication management be treated differently than other types of
beneficiary incentives? If so, how and why?
d. What, if any, disclosures should OIG require the offeror to make
to beneficiaries regarding an incentive (e.g., the source of the
incentive)?
ii. Please identify (and provide citations to) any recent studies
assessing the positive or negative effects of beneficiary incentives on
patient care or patient engagement.
iii. In the context of beneficiary incentives, please identify any
risks or benefits from the following types of potential remuneration,
as well as any safeguards to mitigate risks, and describe how these
terms should be defined for purposes of any rulemaking related to
coordinated care or value-based arrangements:
a. Cash equivalent
b. Gift card
c. In-kind items and services
d. Nonmonetary remuneration
iv. To promote care coordination and value-based care, should OIG
amend its ``Office of Inspector General Policy Statement Regarding
Gifts of Nominal Value To Medicare and Medicaid
[[Page 43610]]
Beneficiaries'' \6\ to increase ``nominal value'' from no more than $15
per item or $75 in the aggregate per patient on an annual basis? If so,
why? Please provide data or other support for any suggested changes in
the dollar amounts. Also, please provide input on whether OIG should
have a similar policy under the anti-kickback statute and, if so, how
such policy would contribute to care coordination or value-based care.
---------------------------------------------------------------------------
\6\ OIG, Office of Inspector General Policy Statement Regarding
Gifts of Nominal Value To Medicare and Medicaid Beneficiaries (Dec.
7, 2016), available at https://oig.hhs.gov/fraud/docs/alertsandbulletins/OIG-Policy-Statement-Gifts-of-Nominal-Value.pdf.
---------------------------------------------------------------------------
B. Cost-Sharing Obligations
i. We are interested in input about how relieving or eliminating
beneficiary cost-sharing obligations might improve care delivery,
enhance value-based arrangements, and promote quality of care. Please
describe any patient care scenarios in which cost-sharing obligations
are particularly problematic.
ii. Please describe the financial impact on providers, suppliers,
and other entities, as well as the fraud and abuse risks, if cost-
sharing amounts could be waived (i.e., the amount owed is not paid) by
participants in a care coordination or value-based arrangement. What,
if any, concerns arise if cost-sharing obligations could be subsidized
by providers, suppliers, or other entities in a care delivery
arrangement?
iii. Please describe any risks to beneficiaries and Federal health
care programs from the reduction or elimination of cost-sharing
obligations.
iv. Please describe any suggested protections or safeguards that
OIG should incorporate if we were to create a safe harbor for certain
beneficiary cost-sharing waiver or subsidy arrangements.
3. Other Related Topics of Interest
A. Current Fraud and Abuse Waivers
i. Please provide feedback on the current waivers developed for the
purposes of testing models by the Center for Medicare and Medicaid
Innovation (Innovation Center) and carrying out the Medicare Shared
Savings Program (MSSP).\7\ Feedback from parties who are using or who
are eligible to use those waivers would be helpful as we consider the
issues raised in this RFI. For example, we are interested in the
following:
---------------------------------------------------------------------------
\7\ CMS, Fraud and Abuse Waivers for Select CMS Models and
Programs, available at https://www.cms.gov/Medicare/Fraud-and-Abuse/PhysicianSelfReferral/Fraud-and-Abuse-Waivers.html.
---------------------------------------------------------------------------
a. How, if at all, have stakeholders found compliance with the
waiver conditions challenging? Please be as specific as possible.
b. Are any waiver requirements particularly burdensome, such that
they impede the goals of the models, initiatives, or programs? If so,
please specify which waiver requirements and why they impede the goals
of the model, initiative, or program.
c. What waiver structures or conditions, if any, work well? Should
OIG consider any waiver structures or conditions for any future safe
harbors or exceptions related to care coordination and value-based care
(including beneficiary incentives to promote patient engagement)?
Please be as specific as possible and provide reasons.
d. One of the key safeguards to mitigate the risk of fraud or abuse
from arrangements protected by the pre-participation and participation
waivers developed pursuant to the MSSP, the Next Generation ACO Model's
participation waiver, and the Pioneer ACO Model's participation waiver
\8\ is the involvement of the accountable care organization's (ACO's)
governing body in the authorization of each arrangement. We are
interested in feedback on how the ACO governing body concept is
working, and whether and if so how, it could be applied to safe harbors
or exceptions for alternative payment models and coordinated care
arrangements.
---------------------------------------------------------------------------
\8\ The Pioneer ACO model began in 2012, and the final
performance year concluded on December 31, 2016.
---------------------------------------------------------------------------
e. We invite specific feedback regarding the pros and cons of fraud
and abuse protections (e.g., waivers or safe harbors) that are uniform
across different types of CMS-sponsored models, initiatives, and
programs.
B. Cybersecurity-Related Items and Services
i. We are aware of interest in donating or subsidizing
cybersecurity-related items and services to providers and others with
whom they share information. We are interested in information about the
types of cybersecurity-related items or services that entities wish to
donate or subsidize, and how existing fraud and abuse laws may pose
barriers to such arrangements. For example, we are interested in (i)
the types of persons that would be parties to, or benefit from, such
arrangements; (ii) whether any persons should be excluded from such
arrangements; (iii) the particular types of items that would be
involved in such arrangements (e.g., hardware, software, and other
items); and (iv) the types of services that would be involved in such
arrangements (e.g., testing services, training services, monitoring
services, or repair or maintenance services). Other areas of interest
include:
a. How might such items or services reduce cybersecurity risks to
the following: The donor, the recipient, patients, and other nonparties
to the arrangement?
b. Are there technical or legal barriers (besides the physician
self-referral law and the anti-kickback statute) that could prevent or
limit the arrangements?
c. Are there any potential risks or unintended consequences to such
arrangements (e.g., potential for fraud or abuse, information blocking,
or anti-competitive practices) and, if so, how might these risks be
mitigated?
d. Are there any particular risks if HHS takes no action?
C. ACO Beneficiary Incentive Program (Section 50341(b) of the
Bipartisan Budget Act of 2018) \9\
---------------------------------------------------------------------------
\9\ Bipartisan Budget Act of 2018, Public Law 115-123, 115th
Cong. (2018) (enacted).
---------------------------------------------------------------------------
Section 50341(b) of the Bipartisan Budget Act of 2018, which added
section 1128B(b)(3)(K) of the Act, states that ``illegal remuneration''
under the anti-kickback statute does not include ``. . . an incentive
payment made to a Medicare fee-for-service beneficiary by an ACO under
an ACO Beneficiary Incentive Program established under subsection (m)
of section 1899, if the payment is made in accordance with the
requirements of such subsection and meets such other conditions as the
Secretary may establish.''
i. For the purposes of implementing this new statutory exception
through a safe harbor, what, if any, ``other conditions'' should this
safe harbor include as protections or safeguards? Please provide
supporting reasons.
D. Telehealth (Section 50302(c) of the Bipartisan Budget Act of 2018)
\10\
---------------------------------------------------------------------------
\10\ Id.
---------------------------------------------------------------------------
Section 50302(c) of the Bipartisan Budget Act of 2018 creates a new
exception to the definition of ``remuneration'' in the beneficiary
inducements CMP. This exception applies to ``telehealth technologies''
provided on or after January 1, 2019, by a provider of services or a
renal dialysis facility to an individual with end-stage renal disease
(ESRD) who is receiving home dialysis for which payment is being made
under Medicare Part B. Under the statute, ``telehealth technologies''
is a term to be defined by the Secretary. The exception requires that
(i) the telehealth technologies not be offered as part of any
advertisement
[[Page 43611]]
or solicitation; (ii) the telehealth technologies must be provided for
the purpose of furnishing telehealth services related to the patient's
ESRD; and (iii) the provision of the telehealth technologies must
``meet[[hairsp]] any other requirements set forth in regulations
promulgated by the Secretary.''
i. For the purposes of this exception, please provide input on how
``telehealth technologies'' should be defined. Please provide examples
of telehealth technologies that may be used to furnish telehealth
services related to a beneficiary's ESRD (e.g., technologies that
address services on the Medicare telehealth list). Also, please
indicate whether telehealth technologies should include services. If
so, please explain, in detail, what services should be considered
``telehealth technologies.''
ii. For the purposes of this exception, should OIG include
protections or safeguards as ``any other requirements set forth in
regulations promulgated by the Secretary?'' If so, please explain what
protections or safeguards and why.
4. Intersection of Physician Self-Referral Law and Anti-Kickback
Statute
Please share any feedback regarding specific circumstances in which
(i) exceptions to the physician self-referral law and safe harbors to
the anti-kickback statute should align for purposes of the goals of
this RFI; and (ii) exceptions to the physician self-referral law in
furtherance of care coordination or value-based care should not have a
corresponding safe harbor to the anti-kickback statute.
Respondents are encouraged to provide complete but concise and
organized responses, including any relevant data and specific examples.
Respondents are not required to address every issue or respond to every
question discussed in this RFI to have their responses considered. All
responses will be considered, provided they contain information OIG can
use to identify the commenter.
Please note: This is a request for information only. This RFI is
issued solely for information and planning purposes; it does not
constitute a Request for Proposal (RFP), application, proposal
abstract, or quotation. This RFI does not commit the U.S. Government to
contract for any supplies or services or make a grant award. Further,
OIG is not seeking proposals through this RFI and will not accept
unsolicited proposals. Respondents are advised that the U.S. Government
will not pay for any information or administrative costs incurred in
response to this RFI; all costs associated with responding to this RFI
will be solely at the interested party's expense. Not responding to
this RFI does not preclude participation in any future procurement, if
conducted. It is the responsibility of the potential responders to
monitor this RFI announcement for additional information pertaining to
this request. Please note that OIG will not respond to questions about
the policy issues raised in this RFI. Contractor support personnel may
be used to review RFI responses.
Responses to this RFI are not offers and cannot be accepted by the
U.S. Government to form a binding contract or issue a grant.
Information obtained as a result of this RFI may be used by the U.S.
Government for program planning on a nonattribution basis. Respondents
should not include any information that might be considered proprietary
or confidential. This RFI should not be construed as a commitment or
authorization to incur costs for which reimbursement would be required
or sought. All submissions become U.S. Government property and will not
be returned. OIG may publicly post the comments received or a summary
thereof.
IV. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. However, section III of this document does contain a
general solicitation of comments in the form of a request for
information. In accordance with the implementing regulations of the
Paperwork Reduction Act (PRA), specifically 5 CFR 1320.3(h)(4), this
general solicitation is exempt from the PRA. Facts or opinions
submitted in response to general solicitations of comments from the
public, published in the Federal Register or other publications,
regardless of the form or format thereof, provided that no person is
required to supply specific information pertaining to the commenter,
other than that necessary for self-identification, as a condition of
the agency's full consideration, are not generally considered
information subject to the PRA. Consequently, there is no need for
review by the Office of Management and Budget under the authority of
the PRA (44 U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public comments we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble,
and, if we proceed with a subsequent document, we may respond to the
comments in the preamble to that document.
Dated: August 20, 2018.
Daniel R. Levinson,
Inspector General.
[FR Doc. 2018-18519 Filed 8-24-18; 8:45 am]
BILLING CODE 4152-01-P